Although direct links between DPD deficiency and cardiotoxicity are still being clarified, evidence shows that a substantial proportion (39–61%) of severe toxic reactions to fluoropyrimidines—including cardiac events—occur in patients with reduced DPD activity. This evidence concerns the gene DPYD and hyperinsulinemic hypoglycemia, familial, 4.